MedTrace Logo

Geographic Atrophy Treatment Evaluation

NCT00890097 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 772

Last updated 2014-07-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate the safety and efficacy of AL-8309B Ophthalmic Solution versus Vehicle administered as a topical ocular drop for the treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Conditions

Interventions

DRUG

AL-8309B Ophthalmic Solution

DRUG

AL-8309B Vehicle

Inactive ingredients used as placebo comparator

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Sally Scheib, Sr. Clinical Lead · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2012-05-31
Completion
2012-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00890097 on ClinicalTrials.gov